Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol.

Abstract

Five patients with involutional osteoporosis were treated with 24,25 dihydroxycholecalciferol (24,25-(OH)2D3) for 6 months, in doses sufficient to double plasma levels at that time. Dietary calcium absorption transiently improved by nearly 2 mmol Ca per day at 2 weeks, but this effect was lost by 6 months. The calcium and phosphate balances followed the trends in calcium absorption. Only twenty-five dihydroxyvitamin D levels changed little. Histomorphometric and kinetic indices of new bone formation and bone blood flow remained stable but there was an increase in urine hydroxyproline at 6 months, which was of borderline statistical significance. Treatment at this dosage of 24,25(OH)2D3, which increased plasma levels within the physiological range, conferred no measurable long-term benefit on our patients. Larger doses, or combination therapy, may warrant further clinical evaluation in osteoporosis.

• Authors: J Reeve, M Tellez, J R Green, R Hesp, U Elsasser, R Wootton, P Hulme, D Williams, J A Kanis, R G Russell, E B Mawer, P J Meunier
• Journal: Acta endocrinologica (Acta Endocrinol (Copenh)) Vol. 101 Issue 4 Pg. 636-40 (Dec 1982) ISSN: 0001-5598 [Print] Denmark
• PMID: 6984270 (Publication Type: Journal Article)

Chemical References

• Dihydroxycholecalciferols
• 24,25-Dihydroxyvitamin D 3
• Calcium

Topics

• 24,25-Dihydroxyvitamin D 3
• Calcium (metabolism)
• Dihydroxycholecalciferols (blood, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Osteoporosis (drug therapy)
• Time Factors